...
首页> 外文期刊>World Journal of Gastroenterology >Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.
【24h】

Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.

机译:溶酶体相关蛋白跨膜4B-35在癌症中的表达及其与肝细胞癌分化状态的关系。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIM: To produce high-quality polyclonal antibody to lysosome-associated protein transmembrane 4B-35 and to identify LAPTM4B-35 expression in cancer tissues and its correlation with differentiation status of hepatocellular carcinoma (HCC). METHODS: The 297 bp 5' end of LAPTM4B cDNA was obtained by PCR and inserted into prokaryotic expression vector pGEX-KG. Then the recombinant pGEX-KG-N(1-99) was transformed into E.coli JM109 to express GST-fusion protein. The fusion protein was purified by glutathione sepharose(TM) 4B agarose. The purified GST-LAPTM4B-N(1-99) was characterized by SDS-PAGE, and used to immunize rabbits. The titer and specificity of antisera were detected by ELISA and Western blot, respectively. The correlation between the expression levels of LAPTM4B-35 and the differentiation status of HCC was analyzed via Western blot. The expression of LAPTM4B-35 in HCC and other six cancer tissues was investigated via tissue chip and immunohistochemical analysis. RESULTS: About 6.2 mg of pure GST-LAPTM4B-N(1-99) was isolated from 1 L of bacteria. The GST-LAPTM4B-N(1-99) produced high titer antisera in rabbits and showed good immunity. Western blot showed specific reactions for the antibody to the LAPTM4B-35 in the total proteins from HCC tissues and BEL-7402 cells, also to the fusion protein purified or in the transformed bacteria. LAPTM4B-35 was remarkably expressed in several cancers, such as HCC, breast cancer, gastric carcinoma, lung cancer, and colon carcinoma, but not commonly expressed in esophageal cancer and rectum carcinoma. Notably, the expression levels of LAPTM4B-35 were significantly and inversely correlated to the differentiation of HCCs in a 20 case analysis. CONCLUSION: Specific polyclonal antibody (LAPTM4B-N(1-99)-pAb) to LAPTM4B-35 was produced. It identified the expression of LAPTM4B-35 in some cancer tissues originated from single layer cuboidal and columnar epithelial cells and firmly demonstrated that the expression of LAPTM4B-35 in HCC was inversely correlated with the differentiation of HCC.
机译:目的:制备高质量的溶酶体相关蛋白跨膜4B-35多克隆抗体,鉴定LAPTM4B-35在癌组织中的表达及其与肝癌分化状态的相关性。方法:通过PCR获得LAPTM4B cDNA的297 bp 5'端,并将其插入原核表达载体pGEX-KG中。然后将重组pGEX-KG-N(1-99)转化到大肠杆菌JM109中以表达GST融合蛋白。融合蛋白通过谷胱甘肽琼脂糖TM 4B琼脂糖纯化。通过SDS-PAGE表征纯化的GST-LAPTM4B-N(1-99),并用于免疫兔。分别通过ELISA和Western blot检测抗血清的效价和特异性。通过Western blot分析LAPTM4B-35的表达水平与肝癌分化状态的相关性。通过组织芯片和免疫组化分析研究了LAPTM4B-35在肝癌和其他六种癌组织中的表达。结果:从1 L细菌中分离出约6.2 mg的纯GST-LAPTM4B-N(1-99)。 GST-LAPTM4B-N(1-99)在兔中产生高滴度的抗血清,并显示出良好的免疫力。 Western印迹显示HCC组织和BEL-7402细胞的总蛋白中针对LAPTM4B-35的抗体发生特异性反应,也对纯化的或转化的细菌中的融合蛋白产生特异性反应。 LAPTM4B-35在几种癌症(例如HCC,乳腺癌,胃癌,肺癌和结肠癌)中显着表达,但在食管癌和直肠癌中不普遍表达。值得注意的是,在20例病例分析中,LAPTM4B-35的表达水平与HCC的分化显着且呈负相关。结论:产生了针对LAPTM4B-35的特异性多克隆抗体(LAPTM4B-N(1-99)-pAb)。它鉴定了LAPTM4B-35在某些来自单层立方和柱状上皮细胞的癌组织中的表达,并坚定地证明了LAPTM4B-35在肝癌中的表达与肝癌的分化呈负相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号